Skip to content

Comparative analysis of analgesic effects of different concentrations of nalbuphine combined with dexmedetomidine after cesarean section

Comparative study of different concentrations of nalbuprenorphine for postoperative analgesia

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000040194
Enrollment
Unknown
Registered
2020-11-25
Start date
2020-11-25
Completion date
Unknown
Last updated
2021-01-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative analgesia

Interventions

B:add nabuphine 2.0mg/kg + dexmedetomidine 2ug / kg to the postoperative analgesia pump
C: add nabuphine 2.5mg/kg + dexmedetomidine 2ug / kg to the postoperative analgesia pump

Sponsors

Qingdao Women's and Children's Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 35 Years

Inclusion criteria

Inclusion criteria: (1) 37-41 weeks of gestation, single pregnancy, the first cesarean section; (2) 18-35 years of age, ASA I-II patients; (3) patients who did not take opioid analgesics during pregnancy; (4) patients without contraindications to cesarean section.

Exclusion criteria

Exclusion criteria: (1) patients with pregnancy complications such as diabetes mellitus, pregnancy induced hypertension and placental abruption; (2) patients with liver and kidney dysfunction or coagulation dysfunction; (3) patients with opioid allergy or dependence; (4) patients with mental disorders and long-term history of taking analgesics; patients with drug addiction and drug use history.

Design outcomes

Primary

MeasureTime frame
uterine contraction pain after operation;

Secondary

MeasureTime frame
the sedation effect after operation;adverse reactions after operation;PCIA effective press times;postoperative satisfaction;The level of anesthetics in the milk;

Countries

China

Contacts

Public ContactMiqun Wang

Qingdao Women's and Children's Hospital

wmq7903@163.com+86 18553263366

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026